iRhythm Holdings, Inc (IRTC) FinancialsIRTCFinancialiRhythm Holdings, Inc

iRhythm Holdings, Inc (IRTC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Contracted third-party payors, accounting for 50.8% of total sales, equivalent to $113.78M. Other significant revenue streams include Commercial Payors and Centers for Medicare & Medicaid. Understanding this composition is critical for investors evaluating how IRTC navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, iRhythm Holdings, Inc maintains a gross margin of 72.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.57%, while the net margin is -0.17%. These profitability ratios, combined with a Return on Equity (ROE) of -9.63%, provide a clear picture of how effectively IRTC converts its operational activities into shareholder value.

In the context of the broader market, IRTC competes directly with industry leaders such as ITGR and CELC. With a market capitalization of $3.96B, it holds a significant position in the sector. When comparing efficiency, IRTC's gross margin of 72.80% stands against ITGR's 24.71% and CELC's N/A. Such benchmarking helps identify whether iRhythm Holdings, Inc is trading at a premium or discount relative to its financial performance.

iRhythm has demonstrated a gross margin of 72.80% in Q2 2026, which is a strong indicator of its profitability potential. Despite recent losses, the company has shown improving revenue trends, with a total revenue of $224.17 million in Q2 2026, up from $186.69 million in Q2 2025.